Management of Pulmonary Embolism: An Update

Journal of the American College of Cardiology

Volumn 67, Issue 8, 2016, Pages 976-990

  Konstantinides, Stavros V ^a,b   Barco, Stefano ^a   Lankeit, Mareike ^a   Meyer, Guy ^c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

anticoagulation; cava filters; prognosis; reperfusion; risk assessment; venous thromboembolism

Indexed keywords

APIXABAN; DABIGATRAN ETEXILATE; EDOXABAN; RIVAROXABAN; ANTICOAGULANT AGENT;

BLOOD CLOT LYSIS; CANCER PATIENT; CLINICAL EFFECTIVENESS; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DIAGNOSTIC IMAGING; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYSIS; HUMAN; LUNG EMBOLISM; META ANALYSIS (TOPIC); MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION; REVIEW; RISK ASSESSMENT; TREND STUDY; VENA CAVA FILTER; DISEASE MANAGEMENT; FIBRINOLYTIC THERAPY; HEALTH; MORBIDITY; PROCEDURES; PULMONARY EMBOLISM; SURVIVAL RATE; TRENDS;

ANTICOAGULANTS; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; GLOBAL HEALTH; HUMANS; MORBIDITY; PULMONARY EMBOLISM; SURVIVAL RATE; THROMBOLYTIC THERAPY;

EID: 84959019042     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.11.061     Document Type: Review

References (99)

1. G.E. Raskob, P. Angchaisuksiri, A.N. Blanco, et al. for the ISTH Steering Committee for World Thrombosis Day Thrombosis: a major contributor to global disease burden Arterioscler Thromb Vasc Biol 34 2014 2363 2371
2. A.M. Wendelboe, M. McCumber, E.M. Hylek, et al. for the ISTH Steering Committee for World Thrombosis Day Global public awareness of venous thromboembolism J Thromb Haemost 13 2015 1365 1371
3. E. Ceriani, C. Combescure, G. Le Gal, and et al. Clinical prediction rules for pulmonary embolism: a systematic review and meta-analysis J Thromb Haemost 8 2010 957 970
4. S.V. Konstantinides, A. Torbicki, G. Agnelli, and et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism Eur Heart J 35 2014 3033 3069 3069a-3069k
5. M. Righini, J. Van Es, P.L. den Exter, and et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study JAMA 311 2014 1117 1124
6. B.D. Hutchinson, P. Navin, E.M. Marom, and et al. Overdiagnosis of pulmonary embolism by pulmonary CT angiography AJR Am J Roentgenol 205 2015 271 277
7. J.J. Phillips, J. Straiton, and R.T. Staff Planar and SPECT ventilation/perfusion imaging and computed tomography for the diagnosis of pulmonary embolism: a systematic review and meta-analysis of the literature, and cost and dose comparison Eur J Radiol 84 2015 1392 1400
8. A. Le Duc-Pennec, P.Y. Le Roux, J.C. Cornily, and et al. Diagnostic accuracy of single-photon emission tomography ventilation/perfusion lung scan in the diagnosis of pulmonary embolism Chest 141 2012 381 387
9. S. Konstantinides, and S.Z. Goldhaber Pulmonary embolism: risk assessment and management Eur Heart J 33 2012 3014 3022
10. C. Kearon, E.A. Akl, A.J. Comerota, and et al. Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e419S e494S
11. M.R. Jaff, M.S. McMurtry, S.L. Archer, et al. for the American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation Council on Peripheral Vascular Disease, and Council on Arteriosclerosis, Thrombosis and Vascular Biology Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association Circulation 123 2011 1788 1830
12. S. Laporte, P. Mismetti, H. Décousus, et al. for the RIETE Investigators Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry Circulation 117 2008 1711 1716
13. D. Aujesky, D.S. Obrosky, R.A. Stone, and et al. Derivation and validation of a prognostic model for pulmonary embolism Am J Respir Crit Care Med 172 2005 1041 1046
14. D. Jiménez, D. Aujesky, L. Moores, and et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism Arch Intern Med 170 2010 1383 1389
15. M. Righini, P.M. Roy, G. Meyer, and et al. The Simplified Pulmonary Embolism Severity Index (PESI): validation of a clinical prognostic model for pulmonary embolism J Thromb Haemost 9 2011 2115 2117
16. D. Aujesky, P.M. Roy, C.P. Le Manach, and et al. Validation of a model to predict adverse outcomes in patients with pulmonary embolism Eur Heart J 27 2006 476 481
17. M. Lankeit, D. Jiménez, M. Kostrubiec, and et al. Predictive value of the high-sensitivity troponin T assay and the simplified Pulmonary Embolism Severity Index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study Circulation 124 2011 2716 2724
18. D. Aujesky, P.M. Roy, F. Verschuren, and et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial Lancet 378 2011 41 48
19. W. Zondag, I.C. Mos, D. Creemers-Schild, et al. for the Hestia Study Investigators Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study J Thromb Haemost 9 2011 1500 1507
20. M.J. Agterof, R.E. Schutgens, R.J. Snijder, and et al. Out of hospital treatment of acute pulmonary embolism in patients with a low NT-proBNP level J Thromb Haemost 8 2010 1235 1241
21. K. Hellenkamp, A. Kaeberich, J. Schwung, and et al. Risk stratification of normotensive pulmonary embolism based on the sPESI: does it work for all patients? Int J Cardiol 197 2015 162 163
22. M. Lankeit, D. Jiménez, M. Kostrubiec, and et al. Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism Eur Respir J 43 2014 1669 1677
23. D. Jiménez, D. Kopecna, V. Tapson, et al. for the PROTECT Investigators Derivation and validation of multimarker prognostication for normotensive patients with acute symptomatic pulmonary embolism Am J Respir Crit Care Med 189 2014 718 726
24. G. Meyer, E. Vicaut, T. Danays, et al. for the PEITHO Investigators Fibrinolysis for patients with intermediate-risk pulmonary embolism N Engl J Med 370 2014 1402 1411
25. A. Kaeberich, V. Seeber, D. Jiménez, and et al. Age-adjusted high-sensitivity troponin T cut-off value for risk stratification of pulmonary embolism Eur Respir J 45 2015 1323 1331
26. C. Dellas, M. Tschepe, V. Seeber, and et al. A novel H-FABP assay and a fast prognostic score for risk assessment of normotensive pulmonary embolism Thromb Haemost 111 2014 996 1003
27. C. Bova, O. Sanchez, P. Prandoni, and et al. Identification of intermediate-risk patients with acute symptomatic pulmonary embolism Eur Respir J 44 2014 694 703
28. C. Fernández, C. Bova, O. Sanchez, and et al. Validation of a model for identification of patients at intermediate to high risk for complications associated with acute symptomatic pulmonary embolism Chest 148 2015 211 218
29. C. Kearon, and E.A. Akl Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism Blood 123 2014 1794 1801
30. G. Agnelli, H.R. Buller, A. Cohen, et al. for the AMPLIFY Investigators Oral apixaban for the treatment of acute venous thromboembolism N Engl J Med 369 2013 799 808
31. S. Schulman, A.K. Kakkar, S.Z. Goldhaber, et al. for the RE-COVER II Trial Investigators Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis Circulation 129 2014 764 772
32. S. Schulman, C. Kearon, A.K. Kakkar, et al. for the RE-COVER Study Group Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 2009 2342 2352
33. Hokusai-VTE Investigators Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism N Engl J Med 369 2013 1406 1415
34. EINSTEIN-PE Investigators Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N Engl J Med 366 2012 1287 1297
35. EINSTEIN Investigators Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 363 2010 2499 2510
36. N. van Es, M. Coppens, S. Schulman, and et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials Blood 124 2014 1968 1975
37. J. Beyer-Westendorf, K. Förster, S. Pannach, and et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry Blood 124 2014 955 962
38. C.V. Pollack Jr., P.A. Reilly, J. Eikelboom, and et al. Idarucizumab for dabigatran reversal N Engl J Med 373 2015 511 520
39. G. Lu, F.R. DeGuzman, S.J. Hollenbach, and et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa Nat Med 19 2013 446 451
40. M.H. Prins, L. Bamber, S.J. Cano, and et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial Thromb Res 135 2015 281 288
41. L. Bamber, D. Muston, E. McLeod, and et al. Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist Thromb J 13 2015 20
42. F.A. Klok, G. Meyer, and S. Konstantinides Management of intermediate-risk pulmonary embolism: uncertainties and challenges Eur J Haematol 95 2015 489 497
43. G. Meyer, B. Planquette, and O. Sanchez Pulmonary embolism: whom to discharge and whom to thrombolyze? J Thromb Haemost 13 Suppl 1 2015 S252 S258
44. C. Marti, G. John, S. Konstantinides, and et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis Eur Heart J 36 2015 605-14
45. S. Chatterjee, A. Chakraborty, I. Weinberg, and et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis JAMA 311 2014 2414 2421
46. S. Konstantinides Clinical practice. Acute pulmonary embolism N Engl J Med 359 2008 2804 2813
47. C. Wang, Z. Zhai, Y. Yang, et al. for the China Venous Thromboembolism (VTE) Study Group Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial Chest 137 2010 254 262
48. M. Sharifi, C. Bay, L. Skrocki, et al. for the "MOPETT" Investigators Moderate pulmonary embolism treated with thrombolysis (from the "MOPETT" Trial) Am J Cardiol 111 2013 273 277
49. P.W. Armstrong, A.H. Gershlick, P. Goldstein, et al. for the STREAM Investigative Team Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction N Engl J Med 368 2013 1379 1387
50. R.P. Engelberger, and N. Kucher Ultrasound-assisted thrombolysis for acute pulmonary embolism: a systematic review Eur Heart J 35 2014 758 764
51. N. Kucher, P. Boekstegers, O.J. Müuller, and et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism Circulation 129 2014 479 486
52. G. Piazza, B. Hohlfelder, M.R. Jaff, et al. for the SEATTLE II Investigators A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: the SEATTLE II study J Am Coll Cardiol Intv 8 2015 1382 1392
53. W.T. Kuo, A. Banerjee, P.S. Kim, and et al. Pulmonary Embolism Response to Fragmentation, Embolectomy, and Catheter Thrombolysis (PERFECT): initial results from a prospective multicenter registry Chest 148 2015 667 673
54. H. Jarrett, C.J. Zack, V. Aggarwal, and et al. Impact of institutional volume on outcomes of catheter directed thrombolysis in the treatment of acute proximal deep vein thrombosis: a 6-year United States experience (2005-2010) Circulation 132 2015 1127 1135
55. R.P. Engelberger, D. Spirk, T. Willenberg, and et al. Ultrasound-assisted versus conventional catheter-directed thrombolysis for acute iliofemoral deep vein thrombosis Circ Cardiovasc Interv 8 2015 e002027
56. P.D. Stein, F. Matta, and R.D. Hull Increasing use of vena cava filters for prevention of pulmonary embolism Am J Med 124 2011 655 661
57. P.D. Stein, F. Matta, D.C. Keyes, and et al. Impact of vena cava filters on in-hospital case fatality rate from pulmonary embolism Am J Med 125 2012 478 484
58. A. Muriel, D. Jiménez, D. Aujesky, and et al. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk J Am Coll Cardiol 63 2014 1675 1683
59. P. Mismetti, S. Laporte, O. Pellerin, et al. for the PREPIC2 Study Group Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial JAMA 313 2015 1627 1635
60. Z. Jia, A. Wu, M. Tam, and et al. Caval penetration by inferior vena cava filters: a systematic literature review of clinical significance and management Circulation 132 2015 944 952
61. T.P. Shiraev, A. Omari, and R.L. Rushworth Trends in pulmonary embolism morbidity and mortality in Australia Thromb Res 132 2013 19 25
62. F. Dentali, W. Ageno, F. Pomero, and et al. Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy Thromb Haemost 115 2016 399 405
63. S. Agarwal, D. Clark III, K. Sud, and et al. Gender disparities in outcomes and resource utilization for acute pulmonary embolism hospitalizations in the United States Am J Cardiol 116 2015 1270 1276
64. Y. Yang, L. Liang, Z. Zhai, et al. for the Investigators for National Cooperative Project for Prevention and Treatment of PTE-DVT Pulmonary embolism incidence and fatality trends in Chinese hospitals from 1997 to 2008: a multicenter registration study PLoS One 6 2011 e26861
65. B. Park, L. Messina, P. Dargon, and et al. Recent trends in clinical outcomes and resource utilization for pulmonary embolism in the United States: findings from the nationwide inpatient sample Chest 136 2009 983 990
66. R.S. Wiener, L.M. Schwartz, and S. Woloshin Time trends in pulmonary embolism in the United States: evidence of overdiagnosis Arch Intern Med 171 2011 831 837
67. C. Pütter, O. von Beckerath, H.M. Sobik, and et al. Prescription of enoxaparin is associated with decreasing pulmonary embolism mortality rate in Germany J Thromb Thrombolysis 40 2015 468 473
68. J. de Miguel-Diez, R. Jiménez-Garcia, D. Jiménez, and et al. Trends in hospital admissions for pulmonary embolism in Spain from 2002 to 2011 Eur Respir J 44 2014 942 950
69. T. Provias, D.M. Dudzinski, M.R. Jaff, and et al. The Massachusetts General Hospital Pulmonary Embolism Response Team (MGH PERT): creation of a multidisciplinary program to improve care of patients with massive and submassive pulmonary embolism Hosp Pract (1995) 42 2014 31 37
70. J. Tsai, S.D. Grosse, A.M. Grant, and et al. Trends in in-hospital deaths among hospitalizations with pulmonary embolism Arch Intern Med 172 2012 960 961
71. M. Carrier, M. Righini, P.S. Wells, and et al. Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies J Thromb Haemost 8 2010 1716 1722
72. C.E. Mahan, M.E. Borrego, A.L. Woersching, and et al. Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates Thromb Haemost 108 2012 291 302
73. 19F magnetic resonance imaging with targeted perfluorocarbon nanoemulsions Circulation 131 2015 1405 1414
74. P.D. Stein, L.R. Goodman, R.D. Hull, and et al. Diagnosis and management of isolated subsegmental pulmonary embolism: review and assessment of the options Clin Appl Thromb Hemost 18 2012 20 26
75. G. Le Gal, and M. Righini Controversies in the diagnosis of venous thromboembolism J Thromb Haemost 13 Suppl 1 2015 S259 S265
76. J.A. Heit, M.D. Silverstein, D.N. Mohr, and et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study Arch Intern Med 160 2000 809 815
77. J.F. Timp, S.K. Braekkan, H.H. Versteeg, and et al. Epidemiology of cancer-associated venous thrombosis Blood 122 2013 1712 1723
78. M. Carrier, A. Lazo-Langner, S. Shivakumar, et al. for the SOME Investigators Screening for occult cancer in unprovoked venous thromboembolism N Engl J Med 373 2015 697 704
79. A.Y. Lee, P.W. Kamphuisen, G. Meyer, et al. for the CATCH Investigators Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial JAMA 314 2015 677 686
80. M.H. Prins, A.W.A. Lensing, T.A. Brighton, and et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials Lancet Haematol 1 2014 e37 e46
81. M.C. Vedovati, F. Germini, G. Agnelli, and et al. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis Chest 147 2015 475 483
82. N. van Es, M. Di Nisio, S.M. Bleker, and et al. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study Thromb Haemost 114 2015 1268 1276
83. J.R. Crosby, U. Marzec, A.S. Revenko, and et al. Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates Arterioscler Thromb Vasc Biol 33 2013 1670 1678
84. H. Zhang, E.C. Löwenberg, J.R. Crosby, and et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk Blood 116 2010 4684 4692
85. H.R. Büller, C. Bethune, S. Bhanot, et al. for the FXI-ASO TKA Investigators Factor XI antisense oligonucleotide for prevention of venous thrombosis N Engl J Med 372 2015 232 240
86. A. Tosetto, A. Iorio, M. Marcucci, and et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH) J Thromb Haemost 10 2012 1019 1025
87. S. Eichinger, G. Heinze, L.M. Jandeck, and et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model Circulation 121 2010 1630 1636
88. M.A. Rodger, S.R. Kahn, P.S. Wells, and et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy CMAJ 179 2008 417 426
89. F.A. Klok, C. Niemann, C. Dellas, and et al. Performance of five different bleeding-prediction scores in patients with acute pulmonary embolism J Thromb Thrombolysis 2015 Jun 20 [E-pub ahead of print]
90. N. Riva, M. Bellesini, M.N. Di Minno, and et al. Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. A multicentre retrospective cohort study Thromb Haemost 112 2014 511 521
91. G. Palareti, B. Cosmi, C. Legnani, et al. for the DULCIS (D-dimer and ULtrasonography in Combination Italian Study) Investigators D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study Blood 124 2014 196 203
92. C. Kearon, F.A. Spencer, D. O'Keeffe, et al. for the D-Dimer Optimal Duration Study Investigators D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study Ann Intern Med 162 2015 27 34
93. F. Couturaud, O. Sanchez, G. Pernod, et al. for the PADIS-PE Investigators Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: the PADIS-PE randomized clinical trial JAMA 314 2015 31 40
94. S. Schulman, C. Kearon, A.K. Kakkar, et al. for the RE-MEDY Trial Investigators RE-SONATE Trial Investigators Extended use of dabigatran, warfarin, or placebo in venous thromboembolism N Engl J Med 368 2013 709 718
95. G. Agnelli, P. Prandoni, C. Becattini, and et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism Ann Intern Med 139 2003 19 25
96. G. Agnelli, H.R. Buller, A. Cohen, et al. for the AMPLIFY-EXT Investigators Apixaban for extended treatment of venous thromboembolism N Engl J Med 368 2013 699 708
97. F.A. Klok, T. van der Hulle, P.L. den Exter, and et al. The post-PE syndrome: a new concept for chronic complications of pulmonary embolism Blood Rev 28 2014 221 226
98. I.M. Lang, R. Pesavento, D. Bonderman, and et al. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding Eur Respir J 41 2013 462 468
99. L. Guérin, F. Couturaud, F. Parent, and et al. Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism Thromb Haemost 112 2014 598 605